Drgona, L. and Gudiol, C. and Lanini, S. and Salzberger, B. and Ippolito, G. and Mikulska, M. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). CLINICAL MICROBIOLOGY AND INFECTION, 24 (Suppl2). S83-S94. ISSN 1198-743X, 1469-0691
Full text not available from this repository. (Request a copy)Abstract
Background: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. Aims: To review, from an Infectious Diseases perspective, the safety profile of agents targeting CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4 and to suggest preventive recommendations. Sources: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family. Content: The risk and spectrum of infections in patients receiving CD22-targeted agents (i.e. inotuzumab ozogamicin) are similar to those observed with anti-CD20 antibodies. Anti-Pneumocystis prophylaxis and monitoring for cytomegalovirus (CMV) infection is recommended for patients receiving CD30-targeted agents (brentuximab vedotin). Due to the scarcity of data, the risk posed by CD33-targeted agents (gemtuzumab ozogamicin) cannot be assessed. Patients receiving CD38-targeted agents (i.e. daratumumab) face an increased risk of varicella-zoster virus (VZV) infection. Therapy with CD40-targeted agents (lucatumumab or dacetuzumab) is associated with opportunistic infections similar to those observed in hyper-IgM syndrome, and prevention strategies (including anti-Pneumocystis prophylaxis and pre-emptive therapy for CMV infection) are warranted. SLAMF-7 (CD319)-targeted agents (elotuzumab) induce lymphopenia and increase the risk of infection (particularly due to VZV). The impact of CCR4-targeted agents (mogamulizumab) on infection susceptibility is difficult to distinguish from the effect of underlying diseases and concomitant therapies. However, anti-Pneumocystis and antiherpesvirus prophylaxis and screening for chronic hepatitis B virus (HBV) infection are recommended. Implications: Specific management strategies should be put in place to reduce the risk and/or the severity of infectious complications associated to the reviewed agents. (c) 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HYPER-IGM SYNDROME; ANTI-CCR4 MONOCLONAL-ANTIBODY; LOW-DOSE DEXAMETHASONE; MULTICENTER PHASE-II; RECEPTOR 4 ANTIBODY; HEPATITIS-B-VIRUS; GEMTUZUMAB OZOGAMICIN; LEUKEMIA-LYMPHOMA; INOTUZUMAB OZOGAMICIN; Brentuximab vedotin; Daratumumab; Gemtuzumab ozogamicin; Infection; Inotuzumab ozogamicin; Lucatumumab; Mogamulizumab; Moxetumomab pasudotox |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Petra Gürster |
| Date Deposited: | 02 Jul 2020 12:02 |
| Last Modified: | 02 Jul 2020 12:02 |
| URI: | https://pred.uni-regensburg.de/id/eprint/14423 |
Actions (login required)
 |
View Item |
